And then secondly, maybe for the listeners, When people hear the words AI, and maybe in specific, let's say, in clinical trials, what would you say is real versus hype? And maybe help our listeners here understand what to take seriously, what maybe you can kind of ignore.

Yeah, absolutely.

So for us, when we talk with pharmaceutical companies or biotech companies or health provider organizations, when we talk about differentiation, I'm a big fan that you differentiate based on the actual outcome.

So all the software, all the services in the world, it doesn't really mean anything unless you actually have the outcomes that matter.

And for us, we have demonstrable outcomes out in the marketplace.

For example, with one top five biopharma company, we've been able to increase their per patient, per site, per month accrual rates across the portfolio of phase one through three studies by 36% median across their studies.

Some studies were up to 395% faster.

How are these companies all, where are they in their journeys? And how do you kind of fit in with those?